Tamandjou Cynthia Raissa, Maponga Tongai Gibson, Chotun Nafiisah, Preiser Wolfgang, Andersson Monique Ingrid
Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
National Health Laboratory Service (NHLS), Tygerberg Hospital, Tygerberg, South Africa.
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):18. doi: 10.11604/pamj.supp.2017.27.3.11546. eCollection 2017.
This commentary describes the need for a birth dose monovalent hepatitis B virus (HBV) vaccine and an effective programme for the prevention of mother-to-child-transmission (MTCT) of HBV in Africa. Current World Health Organization guidelines recommend routine maternal screening for HBV followed by treatment of highly infectious HBV-infected mothers, and HBV birth dose vaccination and the administration of hepatitis B immunoglobulin for HBV-exposed infants as an effective strategy for the prevention of HBV MTCT. None of these practices are currently in place in most parts of Africa. To date, fewer than 10 African countries vaccinate children at birth against HBV. Despite the hurdles associated with implementing this practice, its expansion to the rest of Africa is feasible and crucial to reducing the global number of new HBV infections by 90% by 2030, as targeted by the current Global Health Strategy for the elimination of viral hepatitis.
本评论阐述了在非洲使用出生剂量单价乙型肝炎病毒(HBV)疫苗以及实施有效预防HBV母婴传播(MTCT)项目的必要性。世界卫生组织现行指南建议对孕产妇进行常规HBV筛查,随后对高传染性HBV感染母亲进行治疗,并对暴露于HBV的婴儿接种出生剂量HBV疫苗和注射乙型肝炎免疫球蛋白,作为预防HBV母婴传播的有效策略。目前,非洲大部分地区均未实施这些措施。迄今为止,只有不到10个非洲国家为新生儿接种HBV疫苗。尽管实施这一措施存在障碍,但将其推广至非洲其他地区是可行的,对于按照当前消除病毒性肝炎全球卫生战略的目标在2030年前将全球新增HBV感染病例数减少90%至关重要。